In addition, HSP90 inhibition can cause aneuploidy, at least in yeast46, raising the possibility of some carcinogenic potential. Hence, as for any drug, the long-term toxicity of new compounds will need to be carefully assessed in large patient cohorts, which should include monitoring for cancer recurrence.